Previous studies have established that afatinib sensitivity correlates with EGFR/ERBB2 co-amplification in gastric cancer [35], highlighting the prospective therapeutic potential of pan-HER inhibitors in clinical practice. This evidence concerns the gene ERBB2 and gastric cancer.